Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | CHAT | P28329 | 2/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 5/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | INSR | P06213 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2428647 | 1.00 | NFE2L2 (0.40) | NFE2L2TRPA1CHATATG4BBCHE | |
| SCHEMBL6090752 | 0.95 | ATG4B (0.42) | NFE2L2TRPA1CHATATG4BBCHE | |
| SCHEMBL6090762 | 0.95 | ATG4B (0.42) | NFE2L2TRPA1CHATATG4BBCHE | |
| SCHEMBL3359315 | 0.90 | ALDH1A1 (0.37) | CHATATG4BTP53INSRKCNH2 | |
| SCHEMBL11206640 | 0.83 | NFE2L2 (0.47) | NFE2L2TRPA1CHATTP53MAPT | |
| SCHEMBL11206645 | 0.83 | NFE2L2 (0.47) | NFE2L2TRPA1CHATTP53MAPT | |
| SCHEMBL27557125 | 0.82 | CHAT (0.40) | NFE2L2TRPA1CHATBCHEACHE | |
| SCHEMBL1830841 | 0.82 | INSR (0.44) | ATG4BMAPTINSRKCNH2 | |
| Iodide SCHEMBL8702272 | 0.81 | RAB9A (0.52) | CHATMAPTSMN1; SMN2 | |
| SCHEMBL9798366 | 0.81 | ALDH3A1 (0.43) | ATG4BBCHEACHEEGFRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276627-B2 | One pot sequential reactions and novel products produced thereby | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2007-10-02 | — | — | US | claimed |
| US-20060224017-A1 | One pot sequential reactions and novel products produced thereby | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2006-10-05 | — | — | US | claimed |
| WO-2022113702-A1 | ELECTROCHROMIC COMPOUND, ELECTROCHROMIC COMPOSITION, AND ELECTROCHROMIC ELEMENT | RICOH COMPANY, LTD. (JP) | 2022-06-02 | — | — | WO | disclosed |
| US-8017807-B2 | Tetrahydroxy compound, method for preparing the tetrahydroxy compound, and photoreceptor using the tetrahydroxy compound | RICOH COMPANY LIMITED (JP) | 2011-09-13 | — | — | US | disclosed |
| US-7276627-B2 | One pot sequential reactions and novel products produced thereby | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276627-B2 | One pot sequential reactions and novel products produced thereby | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070128530-A1 | TETRAHYDROXY COMPOUND, METHOD FOR PREPARING THE TETRAHYDROXY COMPOUND, AND PHOTORECEPTOR USING THE TETRAHYDROXY COMPOUND | RICOH COMPANY, LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20060224017-A1 | One pot sequential reactions and novel products produced thereby | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2006-10-05 | — | — | US | disclosed |
| US-20060224017-A1 | One pot sequential reactions and novel products produced thereby | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060224017-A1 | One pot sequential reactions and novel products produced thereby | PNMT, CYP1A1, TERT | NFE2L2 446/4885TRPA1 1677/4885CHAT 4363/4885 |
| US-20070128530-A1 | TETRAHYDROXY COMPOUND, METHOD FOR PREPARING THE TETRAHYDROXY COMPOUND, AND PHOTORECEPTOR USING THE TETRAHYDROXY COMPOUND | ALDH1A2, SLC9B2, SLC18A2 | NFE2L2 1620/4885TRPA1 302/4885CHAT 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.